EN DE
Watch Jiangsu Yahong Meditech Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Jiangsu Yahong Meditech Co. Ltd. (688176) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Jiangsu Yahong Meditech Co. Ltd. stock ¥2.24, price ¥10.94, upside -79.5%, quality 57 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100005XW0

JY Jiangsu Yahong Meditech Co. Ltd. logo Thin data Oct 30, 2026

Jiangsu Yahong Meditech Co. Ltd.

688176 · SHG
Solid, but very expensive

Our calculation puts a fair price 80% below what the stock costs today.

Low debt
Revenue last quarter +20% vs. a year ago.
Quality 57/100
Mixed Growth (revenue 3y +2098.1 %/yr in CNY)
Fair value ¥2.24 · Strongly overvalued (−79.5%)
Loss-making · -165.5% net margin (TTM)
Negative free cash flow
Trails peers (3/11)
Narrow moat 12/100
Thin data
Watch Jiangsu Yahong Meditech Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥18.07 ¥4.74 Fair Value ¥2.24 Jan 2022 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.

How to read this chart

58‑month range ¥4.74 – ¥18.07 · fair‑value band ¥1.48 – ¥2.80 · the ¥10.94 price screens above the ¥2.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 30, 2026.

Follow Jiangsu Yahong Meditech Co. in your weekly email

Every Wednesday you see whether Jiangsu Yahong Meditech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally.

Show moreShow less

It develops APL-1702, a photodynamic therapy product for the treatment of high-grade squamous intraepithelial lesions of the cervix, as well as for HPV virus clearance indication; APL-1706 and APLD-2304 for non-muscle invasive bladder cancer (NMIBC) diagnosis and surgery indication; APL-1202, an oral reversible MetAP2 inhibitor for untreated intermediate-risk NMIBC and neoadjuvant therapy before muscle-invasive bladder cancer indication, as well as for free-living amoeba infection indication; APL-1501 and APL-2401 to treat urinary system tumors.

The company also develops product candidates for the treatment of breast cancer and gynecological tumors under the APL-2302, APL-2501, AT-018, and AT-021 names.

In addition, it develops APL-1401, a dopamine ß- hydroxylase inhibitor to treat moderate to severe active ulcerative colitis; and APL-2301 for treating infections caused by acinetobacter baumannii. The company was founded in 2010 and is based in Shanghai, China.

Stock analysis

Jiangsu Yahong Meditech Co. Ltd. (688176) currently trades at ¥10.94, while our model-based Fair Value estimate is ¥2.24, 79.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.

Scenario range: ¥1.48 (bear) to ¥2.80 (bull), the price of ¥10.94 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Jiangsu Yahong Meditech Co. Ltd. reported revenue of 277M CNY in FY2025 versus 4.6K CNY in FY2021, a compound +1,468.9%/yr. Reported net income was −419M CNY in FY2025.

Key figures

Market cap 6.1B CNY (≈ $919M) Small · P/S ratio 20.0 · EPS (TTM) ¥−0.9300 · Dividend yield 0.1% · Return on equity −36.9% · Return on assets (EBIT) −14.0% · Operating margin −115% · Revenue (TTM) 320M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 38% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −80%, 688176 screens richer than that median.

Fair Value models

Bear ¥1.48 Fair Value ¥2.24 Bull ¥2.80
Price ¥10.94 · Upside -79.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) ¥1.48 ¥2.24 ¥2.80 55
All 1 models by family
Asset-Based
NCAV (Graham) ¥1.48 ¥2.24 ¥2.80 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 78
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 40
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 32
Distance to the 52-week high, does not count
New shares 96
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+37.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2,098.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,211,061.3% (2021) → −155.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

688176 screens overvalued: fair value 80% below the price. Compare with Merck KGaA →

Compare Jiangsu Yahong Meditech Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 570 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 57 · Above median
Fair Value upside −79.5% · Bottom 25%
Profitability
Return on assets −20.4% · Bottom 25%
Net margin (12 months) −165.5% · Bottom 25%
Operating margin (12 months) −114.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 20.2% · Top 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 3.88× · Priciest 25%
P/S (12 months) 19.14× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 20
FUTURE (revenue growth)100 · sector 26
PAST (return on equity)0 · sector 28
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)1 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $78.23 $110.26 +41% vs 688176
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.62 ¥53.48 +10% vs 688176
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,751 ₹1,926 +10% vs 688176
Haleon plc HLN $8.57 $8.57 +0% vs 688176
Merck KGaA MRK €150.30 €109.18 −27% vs 688176
Galderma Group GALD CHF 185.00 CHF 111.00 −40% vs 688176
Takeda Pharmaceutical Company TAK $20.01 $11.39 −43% vs 688176
Sandoz Group SDZ CHF 79.88 CHF 40.33 −50% vs 688176
Teva Pharmaceutical Industries Limited TEVA $41.47 $20.82 −50% vs 688176
Divi's Laboratories Limited DIVISLAB ₹9,506 ₹1,871 −80% vs 688176

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jiangsu Yahong Meditech Co. Ltd. · Fair Value
¥2.24 −80%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Jiangsu Yahong Meditech Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/688176

Frequently asked questions

Is Jiangsu Yahong Meditech Co. Ltd. (688176) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of ¥2.24 versus a price of ¥10.94, about −80% upside (overvalued).
What is the fair value of 688176?
Our model-based fair value for Jiangsu Yahong Meditech Co. Ltd. is ¥2.24 (as of Oct 30, 2026), built from audited fundamentals. The current price: ¥10.94.
What is the quality score of 688176?
Jiangsu Yahong Meditech Co. Ltd. has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jiangsu Yahong Meditech Co. Ltd. (688176)?
Our model-based price target is the fair value of ¥2.24 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario ¥1.48, optimistic scenario ¥2.80. It is a calculation from audited fundamentals, not an analyst target.
What is the Jiangsu Yahong Meditech Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥2.24, about −80% upside versus a price of ¥10.94 (overvalued). Cautious scenario ¥1.48, optimistic scenario ¥2.80. The calculation is refreshed regularly with new filings.
What is the revenue of Jiangsu Yahong Meditech Co. Ltd. (688176)?
Jiangsu Yahong Meditech Co. Ltd. reported trailing-twelve-month revenue of about 320M CNY (latest available figure, as of Oct 30, 2026).
Does Jiangsu Yahong Meditech Co. Ltd. pay a dividend?
Jiangsu Yahong Meditech Co. Ltd. currently shows a dividend yield of 0.06% relative to its recent price (as of Oct 30, 2026).
What is the intrinsic value of Jiangsu Yahong Meditech Co. Ltd. (688176)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jiangsu Yahong Meditech Co. Ltd. it is ¥2.24 per share (as of Oct 30, 2026), against a price of ¥10.94. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Jiangsu Yahong Meditech Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 30, 2026, 688176 trades above its calculated fair value: price ¥10.94, fair value ¥2.24, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688176?
No. The price is what the market pays today (¥10.94); the fair value is what the company's own numbers justify (¥2.24). For Jiangsu Yahong Meditech Co. Ltd. the two are ¥8.70 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jiangsu Yahong Meditech Co. Ltd. worth?
The market values Jiangsu Yahong Meditech Co. Ltd. at about 6.1B CNY (market capitalisation, as of Oct 30, 2026). Per share that is ¥10.94; our models calculate a fair value of ¥2.24 per share.
What do the bullish and bearish scenarios say about 688176?
Our models span a range for Jiangsu Yahong Meditech Co. Ltd.: cautious scenario ¥1.48, base ¥2.24, optimistic ¥2.80 per share (as of Oct 30, 2026, price ¥10.94). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jiangsu Yahong Meditech Co. Ltd. (688176)?
Balance-sheet figures for Jiangsu Yahong Meditech Co. Ltd. (as of Oct 30, 2026): return on equity −36.9%, debt of 0.03 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 688176 from its 52-week high?
Jiangsu Yahong Meditech Co. Ltd. trades at ¥10.94, about 38% below its 52-week high of ¥17.66 and 19% above the low of ¥9.19 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.24 is for.
Which stocks are comparable to Jiangsu Yahong Meditech Co. Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jiangsu Yahong Meditech Co. Ltd. stock attractive at the current price?
The data as of Oct 30, 2026: price ¥10.94, calculated fair value ¥2.24 (−80%), Quality Score 57/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688176 calculated?
We run Jiangsu Yahong Meditech Co. Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥2.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Jiangsu Yahong Meditech Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jiangsu Yahong Meditech Co. Ltd. (688176)?
The closing price on Oct 30, 2026 was ¥10.94. Our model-based fair value is ¥2.24, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jiangsu Yahong Meditech Co. Ltd. right now?
The price sits above even our optimistic bull case (¥2.80). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥1.48 to ¥2.80) leaves room in how you read the outcome.

Key figures of Jiangsu Yahong Meditech Co. Ltd.

How large is the market capitalisation of Jiangsu Yahong Meditech Co. Ltd. (688176)?
The market capitalisation of Jiangsu Yahong Meditech Co. Ltd. is 6.1B CNY (≈ $919M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jiangsu Yahong Meditech Co. Ltd. (688176)?
The price-to-sales ratio of Jiangsu Yahong Meditech Co. Ltd. is 20.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jiangsu Yahong Meditech Co. Ltd. (688176)?
Earnings per share at Jiangsu Yahong Meditech Co. Ltd. are ¥−0.9300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jiangsu Yahong Meditech Co. Ltd. (688176)?
The dividend yield of Jiangsu Yahong Meditech Co. Ltd. is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of Jiangsu Yahong Meditech Co. Ltd. (688176)?
The return on equity (ROE) of Jiangsu Yahong Meditech Co. Ltd. is −36.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jiangsu Yahong Meditech Co. Ltd. (688176)?
On an EBIT basis the return on assets of Jiangsu Yahong Meditech Co. Ltd. is −14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jiangsu Yahong Meditech Co. Ltd. (688176)?
The operating margin of Jiangsu Yahong Meditech Co. Ltd. is −115% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jiangsu Yahong Meditech Co. Ltd. (688176)?
Revenue at Jiangsu Yahong Meditech Co. Ltd. is growing +20.2% versus a year earlier (3y avg +2,098%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Jiangsu Yahong Meditech Co. Ltd. (688176) generate?
The free cash flow of Jiangsu Yahong Meditech Co. Ltd. is −431M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Jiangsu Yahong Meditech Co. Ltd. (688176) hold?
Jiangsu Yahong Meditech Co. Ltd. holds more cash than debt, 512M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Jiangsu Yahong Meditech Co. Ltd. in the live analysis

One click puts Jiangsu Yahong Meditech Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.